WALTHAM, MA and ABBOTT PARK, IL - PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, and Abbott, a global, broad-based health care company, today announced that the companies will jointly present on the applications of exact mass Time-of-Flight (TOF) mass spectrometry for advancing pathogen detection research at the American Society for Mass Spectrometry (ASMS) Conference in Salt Lake City.
The companies' presentation is based on their work together incorporating PerkinElmer's exact mass TOF technology as part of Abbott's PLEX-ID detection platform, employed in pathogen detection research. Currently intended for research and non-diagnostic use only, PLEX-ID is the only high-throughput technology that offers rapid and broad identification, detailed genotyping, and characterization and recognition of emerging organisms.
The PLEX-ID system employs a combination of molecular technologies, including polymerase chain reaction (PCR) for gene amplification and exact mass TOF analysis to rapidly characterize known and unknown organisms. It is designed to address a significant unmet need by providing test results in six to seven hours instead of three or more days as required with current laboratory methods.
"PLEX-ID addresses the unmet needs and complex challenges of microbial identification by detecting and characterizing both known and previously unknown organisms found in a variety of specimens," said Stafford O'Kelly, head of Abbott's molecular diagnostics business. "Our collaboration with PerkinElmer and their expertise in mass TOF gives us the ability to offer laboratories rapid detection and correct identification of a broad range of pathogens."
"Our relationship with Abbott in pathogen measurement via exact mass TOF complements extensive PerkinElmer programs in environmental applications and research. We are delighted to collaborate with Abbott in this important endeavor for real time microbial identification," said Dick Begley, president, Emerging Technologies, PerkinElmer.
Exact mass TOF is a proven technique for detecting analytes by accelerating ions and measuring mass-to-charge ratio from which molecular weight is determined - giving researchers the benefits of high sensitivity, resolution and accuracy in their detection workflows. The technology was developed for ease of use and for either standalone platform use, or OEM incorporation into other measurement systems.
For more information about PerkinElmer's TOF and LC/MS single quad products, and to learn more details about PerkinElmer's collaboration with Abbott, please visit PerkinElmer's hospitality suite at the American Society for Mass Spectrometry (ASMS) conference in Salt Lake City, Utah, from May 23 to May 27.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 83,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at www.abbott.com.
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $1.8 billion in 2009, has about 8,800 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
Corporate Public Relations
Public Affairs, Diagnostics